Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 461-463 |
Seitenumfang | 3 |
Fachzeitschrift | The Lancet Psychiatry |
Jahrgang | 5 |
Ausgabenummer | 6 |
DOIs |
|
Publikationsstatus | Veröffentlicht - Juni 2018 |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
Zugriff auf Dokument
Andere Dateien und Links
Dieses zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
in: The Lancet Psychiatry, Jahrgang 5, Nr. 6, 06.2018, S. 461-463.
Publikation: Beitrag in Fachzeitschrift › Kommentar/Debatte
TY - JOUR
T1 - Antidepressants might work for people with major depression
T2 - where do we go from here?
AU - Cipriani, Andrea
AU - Salanti, Georgia
AU - Furukawa, Toshi A.
AU - Egger, Matthias
AU - Leucht, Stefan
AU - Ruhe, Henricus G.
AU - Turner, Erick H.
AU - Atkinson, Lauren Z.
AU - Chaimani, Anna
AU - Higgins, Julian P.T.
AU - Ogawa, Yusuke
AU - Takeshima, Nozomi
AU - Hayasaka, Yu
AU - Imai, Hissei
AU - Shinohara, Kiyomi
AU - Tajika, Aran
AU - Ioannidis, John P.A.
AU - Geddes, John R.
N1 - Funding Information: ACi is supported by the NIHR Oxford cognitive health Clinical Research Facility. JRG is an NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. TAF has received lecture fees from Eli Lilly, Janssen, Meiji, Mitsubishi-Tanabe, MSD, and Pfizer and consultancy fees from Takeda Science Foundation. He has received research support from Mochida and Mitsubishi-Tanabe. SL has received honoraria for consulting and advisory boards from Alkermes, Eli Lilly, Janssen, Johnson & Johnson, Lundbeck, MedAvante, Roche, Otsuka, and Teva; lecture honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Johnson & Johnson, Lundbeck (Institute), Pfizer, Sanofi-Aventis, ICON, AbbVie, AOP Orphan, and Servier; for the preparation of educational material and publications from Lundbeck Institute and Roche; and Eli Lilly has provided medication for a trial with SL as the primary investigator. NT has received lecture fees from Otsuka and Meiji. YH has received lecture fees from Yoshitomi. All other authors declare no competing interests.
PY - 2018/6
Y1 - 2018/6
UR - http://www.scopus.com/inward/record.url?scp=85044952922&partnerID=8YFLogxK
U2 - 10.1016/S2215-0366(18)30133-0
DO - 10.1016/S2215-0366(18)30133-0
M3 - Comment/debate
C2 - 29628364
AN - SCOPUS:85044952922
SN - 2215-0366
VL - 5
SP - 461
EP - 463
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
IS - 6
ER -